nach oben

Diabetologia

Erschienen in:

01.12.2009 | Review

Medial arterial calcification in diabetes and its relationship to neuropathy

verfasst von: W. J. Jeffcoate, L. M. Rasmussen, L. C. Hofbauer, F. L. Game

Erschienen in: Diabetologia | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Calcification of the media of arterial walls is common in diabetes and is particularly associated with distal symmetrical neuropathy. Arterial calcification also complicates chronic kidney disease and is an independent risk factor for cardiovascular and all-cause mortality. The term calcification is not strictly accurate because the morphological changes incorporate those of new bone formation, i.e. ossification. The processes are complex, but are closely related to those involved in bone homeostasis, and it is relevant that calcification of the arterial wall and osteopenia often co-exist. One particular factor linked to the development of arterial calcification is distal symmetrical neuropathy; indeed, it has been suggested that neuropathy explains the distal distribution of arterial calcification in diabetes. It has also been suggested that the link with neuropathy results from loss of neuropeptides, such as calcitonin gene-related peptide, which are inherently protective. The association between distal symmetrical neuropathy and calcification of the arterial wall highlights the fact that neuropathy may be an independent risk factor for cardiovascular mortality.

Mönckeberg JG (1903) Uber die reine Mediaverkalkung der Exrtremitätenarterien und ihr Verhalten zur Arteriosklerose. Virchows Arch (Pathol Anat) 171:141–167 (article in German)CrossRef

Everhart JE, Pettit DJ, Knowler WC, Rose FA, Bennett PH (1988) Medial artery calcification and its association with mortality and complications of diabetes. Diabetologia 31:16–23PubMed

Lehto S, Niskanen L, Suhonen M, Rönnemaa T, Laakso M (1996) Medial artery calcification: a neglected harbinger of cardiovascular complications in non-insulin dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16:978–983PubMed

Virchow R (1863) Cellular pathology as based upon physiological and pathological histology. Dover, New York

Vattikuti R, Towler DA (2003) Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol: Endocrinol Metab 286:E686–E696CrossRef

Neven E, Dauwe S, De Broe ME, D’Hause PC, Persy V (2007) Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int 72:574–581CrossRefPubMed

Collin-Osdoby P (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95:1046–1057CrossRefPubMed

Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24:1161–1170CrossRefPubMed

Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H (2005) Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 96:717–722CrossRefPubMed

10.

Hofbauer LC, Brueck CC, Sanahan CM, Schoppet M, Dobnig H (2007) Vascular calcification and osteoporosis—from clinical observation towards molecular understanding. Osteoporos Int 18:251–259CrossRefPubMed

11.

Moe SM, Chen NX (2004) Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95:560–567CrossRefPubMed

12.

Abedin M, Tintut Y, Demer LL (2004) Mesenchymal stem cells and the artery wall. Circ Res 95:671–676CrossRefPubMed

13.

Boström K, Watson KE, Horn S, Wortham C, Hennan IM, Demer LL (1993) Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91:1800–1809CrossRefPubMed

14.

Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–220PubMed

15.

Kirton JP, Crofts NJ, George SJ, Brennan K, Canfield AE (2007) Wnt/beta-catenin signalling stimulates chondrogenic and inhibits adipogenic differentiation of pericytes: potential relevance to vascular disease. Circ Res 101:581–589CrossRefPubMed

16.

Shao JS, Cai J, Towler DJ (2006) Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 26:1423–1430CrossRefPubMed

17.

Nguyen KQ, Olesen P, Ledet T, Rasmussen LM (2007) Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells. Endocr 32:52–58CrossRef

18.

Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM (2003) Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 23:489–494CrossRefPubMed

19.

Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden AG (2007) The activin A-follistatin system: potent regulator of human extravascular matrix mineralization. FASEB J 21:2949–2960CrossRefPubMed

20.

Bartholin L, Guindon S, Martel S, Corbo L, Rimokh R (2007) Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter. Gene 393:153–162CrossRefPubMed

21.

Hayashi Y, Maeshima K, Got F, Kojima I (2007) Activin A as a critical mediator of capillary formation: interaction with the fibroblast growth factor action. Endocr J 54:311–318CrossRefPubMed

22.

Pavelock KA, Girard BM, Schutz KC, Braas KM, May V (2007) Bone morphogenetic protein down-regulation of neuronal pituitary adenylate cyclase-activating polypeptide and reciprocal effects on vasoactive intestinal peptide expression. J Neurochem 100:603–616CrossRefPubMed

23.

Anderson HC (1995) Molecular biology of matrix vesicles. Clin Orthop Relat Res 314:266–280PubMed

24.

Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M (2008) Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 102:1529–1538CrossRefPubMed

25.

Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ (1996) The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 39:946–951CrossRefPubMed

26.

Greenwald SE (2007) Ageing of the conduit arteries. J Pathol 211:157–172CrossRefPubMed

27.

Simionescu A, Simionescu DT, Vyavahare NR (2007) Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-β1. Am J Pathol 171:116–123CrossRefPubMed

28.

Collett GDM, Canfield AE (2005) Angiogenesis and pericytes in the initiation of ectopic calcification. Circ Res 96:930–938CrossRefPubMed

29.

Wang Y, Wan C, Deng L et al (2007) The hypoxia-inducible factor α pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 117:1616–1626CrossRefPubMed

30.

Li X, Hsueh-Ying Y, Giachelli CM (2006) Role of the sodium-dependent cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98:905–912CrossRefPubMed

31.

Burke AP, Kolodgie FD, Virmani R (2007) Fetuin-A, valve calcification, and diabetes: what do we understand? Circulation 115:2464–2467CrossRefPubMed

32.

Westenfeld R, Jahnen-Dechent W, Ketteler M (2007) Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med 17:124–128CrossRefPubMed

33.

Boström K, Tsao D, Shen S, Wang Y, Demer LL (2001) Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem 276:14044–14052PubMed

34.

Price PA, Caputo JM, Williamson MK (2002) Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla Protein: biochemical evidence for the cancellous bone-remodelling compartment. J Bone Miner Res 7:1171–1179CrossRef

35.

Wada T, McKee MD, Steitz GCM (1999) Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 84:166–178PubMed

36.

Takemoto M, Yokote K, Nishimura M et al (2000) Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 20:624–628PubMed

37.

Hofbauer LC, Schoppet M (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 358:257–259CrossRefPubMed

38.

Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323–6331CrossRefPubMed

39.

Bucay N, Safosi I, Dunstan CR et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268CrossRefPubMed

40.

Schoppett M, Al-Fakhari N, Franke FE et al (2004) Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-κB ligand in Mönckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab 89:4104–4112CrossRef

41.

Al-Aly Z (2008) Arterial calcification: a tumor necrosis factor-alpha mediated vascular Wnt-opathy. Transl Res 151:233–239CrossRefPubMed

42.

Panizo S, Cardus A, Encinas M et al (2009) RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104:1041–1048CrossRefPubMed

43.

Olesen P, Ledet T, Rasmussen LM (2005) Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 48:561–568CrossRefPubMed

44.

Kanno Y, Into T, Lowenstein CJ, Matsushita K (2008) Nitric oxide regulates vascular calcification by interfering with TGF-signalling. Cardiovasc Res 77:221–230CrossRefPubMed

45.

Parhami F, Basseri B, Hwang J, Tintut Y, Demer LL (2002) High-density lipoprotein regulates calcification of vascular cells. Circ Res 91:570–576CrossRefPubMed

46.

Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z (2005) Regulation of bone morphogenetic protein-2 expression in endothelial cells. Circulation 111:2364–2372CrossRefPubMed

47.

Kim CH, You L, Yellowley CE, Jacobs CR (2006) Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signalling. Bone 39:1043–1047CrossRefPubMed

48.

Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM (2008) Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 51:2100–2107CrossRefPubMed

49.

Selby PL, Shearing PA, Marshall SM (1995) Hydroxyproline excretion is increased in diabetes mellitus and related to the presence of microalbuminuria. Diabet Med 12:240–243CrossRefPubMed

50.

Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM (2006) Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 149:39–42CrossRef

51.

Psyrogiannis A, Kyriazopoulou V, Vagenakis AG (1999) Medial arterial calcification is frequently found in patients with microalbuminuria. Angiology 50:971–975CrossRefPubMed

52.

Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625CrossRefPubMed

53.

Wang CC, Sorribas V, Sharma G, Levi M, Draznin B (2007) Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport. Atherosclerosis 195:e65–e75CrossRefPubMed

54.

Browner WS, Lui L-Y, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocrinol Metab 86:631–637CrossRefPubMed

55.

Schoppett M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024–1028CrossRef

56.

Avignon A, Sultan A, Piot A et al (2005) Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28:2176–2180CrossRefPubMed

57.

Rasmussen LM, Tarnow L, Hansen TK, Parving H-H, Flyvbjerg A (2006) Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 154:75–81CrossRefPubMed

58.

Anand DV, Lahiri A, Lim E, Hopkins D, Corder R (2006) The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47:1850–1857CrossRefPubMed

59.

Kim SM, Lee J, Ryu OH et al (2005) Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf) 63:594–598CrossRef

60.

Secchiero P, Corallini F, Pandolfi A et al (2006) An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236–2244CrossRefPubMed

61.

Edmonds ME, Morrison N, Laws JW, Watkins PJ (1982) Medial arterial calcification and diabetic neuropathy. BMJ 284:928–930CrossRefPubMed

62.

Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR (1993) Medial artery calcification in the feet of diabetic patients and matched non-diabetic controls. Diabetologia 36:615–621CrossRefPubMed

63.

Mayfield JA, Caps MT, Boyko EJ, Ahroni JH, Smith DG (2002) Relationship of medial arterial calcinosis to autonomic neuropathy and adverse outcomes in a diabetic veteran population. J Diabet Compl 16:165–171CrossRef

64.

Sinha S, Munichoodappa CS, Kozak GP (1972) Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). Medicine (Baltimore) 51:191–210CrossRef

65.

Jeffcoate WJ, Game F, Cavanagh PR (2005) The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366:2058–2061CrossRefPubMed

66.

Laroche M, Delmotte A (2005) Increased arterial calcification in Paget’s disease of bone. Calcif Tissue Int 77:129–133CrossRefPubMed

67.

Goebel FD, Füessel HS (1983) Mönckeberg’s sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetologia 24:347–350CrossRefPubMed

68.

Maguire AM, Craig ME, Craighead A et al (2007) Autonomic nerve testing predicts the development of complications. Diabetes Care 30:77–82CrossRefPubMed

69.

Forst T, Pfützner A, Kann P, Lobmann R, Schäfer H, Beyer J (1995) Association between diabetic-autonomic-C-fibre-neuropathy and medial wall calcification in the outcome of trophic foot lesions. Exp Clin Endocrinol Diabetes 103:94–98CrossRefPubMed

70.

Naot D, Cornish J (2008) The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone 43:813–818CrossRefPubMed

71.

Zochodne DW, Verge VM, Cheng C, Sun H, Johnston J (2001) Does diabetes target ganglion neurones ? Progressive sensory neurone involvement in long-term experimental diabetes. Brain 124:2319–2334CrossRefPubMed

72.

Jiang Y, Nyengaard JG, Zhang JS, Jakobsen J (2004) Selective loss of calcitonin gene-related peptide-expressing primary sensory neurons of the a-cell phenotype in early and experimental diabetes. Diabetes 53:2669–2675CrossRefPubMed

73.

La Fontaine J, Harkless LB, Sylvia VL, Carnes D, Heim-Hall J, Jude E (2008) Levels of endothelial nitric oxide synthase and calcitonin gene-related peptide in the Charcot foot: a pilot study. J Foot Ankle Surg 47:424–429CrossRefPubMed

74.

McDougall JJ, Yeung G, Leonard CA, Bray RC (2000) A role for calcitonin gene-related peptide in rabbit knee joint ligament healing. Can J Physiol Pharmacol 78:535–540CrossRefPubMed

75.

Lerner UH (2006) Deletions of genes encoding calcitonin/alpha-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptors in bone. J Musculoskelet Neuronal Interact 6:87–95PubMed

76.

Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR (2001) Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29:162–168CrossRefPubMed

77.

Mancini L, Moradi-Bidhendi N, Brandi ML, Perretti M, MacIntyre I (2001) Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. Biochem Biophys Res Comm 279:391–397CrossRef

78.

Villa I, Mrak E, Rubinacci A, Ravasi F, Guidobono F (2006) CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway. Am J Physiol Cell Physiol 291:C529–C537CrossRefPubMed

79.

Yamaguchi M, Kojima T, Kanekawa M, Alhara N, Nogimura A, Kasai K (2004) Neuropeptides stimulate production of interleukin-6, and tumor necrosis factor-alpha in human dental pulp cells. Inflamm Res 53:199–204CrossRefPubMed

80.

Martin CD, Jimenez-Andrade JM, Ghilardi JR, Mantyh PW (2007) Organization of a unique net-like meshwork of CGRP+ sensory fibers in the mouse periosteum: implications for the generation and maintenance of bone fracture pain. Neurosci Lett 427:148–152CrossRefPubMed

81.

Elefteriou E, Ahn JD, Takeda S et al (2005) Leptin regulation of bone resorption by the sympathetic nervous system. Nature 434:514–520CrossRefPubMed

82.

Ishizuka K, Hirukawa K, Nakamura H, Togari A (2005) Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci Lett 379:47–51CrossRefPubMed

83.

Armano S, Atai M, Goto S, Togari A (2007) Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochim Biophys Acta 1770:966–973

84.

Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappa-B-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 173:2373–2382PubMed

85.

Ono K, Tsuchida A, Kawai H et al (2003) Ankle-brachial blood pressure index predicts all-cause mortality in haemodialysis patients. J Am Soc Nephrol 14:1591–1598CrossRefPubMed

86.

Tussaint ND, Kerr PG (2007) Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology (Carlton) 12:500–509CrossRef

87.

Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JP (2008) Relationship between risk factors and mortality in type 1 diabetic patients in Europe. Diabetes Care 31:1360–1366CrossRefPubMed

88.

Forsblom CM, Sane T, Groop PH et al (1998) Risk factors for mortality in Type II (non-insulin dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 41:1253–1262CrossRefPubMed

89.

Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH (2000) Showing neuropathy is related to increased mortality in diabetic patients—a survival analysis using an accelerated failure time model. J Clin Epidemiol 53:519–523CrossRefPubMed

90.

Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H (1996) Predictors of mortality in insulin-dependent diabetes: 10 year observational follow-up study. BMJ 313:779–784PubMed

91.

Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E (1995) Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabet Med 12:149–155CrossRefPubMed

92.

Olson JC, Erbey JR, Williams KV et al (2002) Subclinical atherosclerosis and estimated glucose disposal rate as predictors of mortality in type 1 diabetes. Ann Epidemiol 12:331–337CrossRefPubMed

93.

Son BK, Kozaki K, Iijima K et al (2006) Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axi survival pathway. Circ Res 98:1024–1031CrossRefPubMed

94.

Trion A, Schutte-Bart C, Bax WH, Jukema JW, van der Laarso A (2008) Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination. Mol Cell Biochem 308:25–33CrossRefPubMed

95.

Xu YG, Zhou SH, Li YG et al (2007) The mechanism underlying vascular smooth muscle cell apoptosis induced by atorvastatin may be mainly associated with down-regulation of survivin expression. Cardiovasc Drugs Ther 21:145–153CrossRefPubMed

96.

Terry JG, Carr JJ, Kouba EO et al (2007) Effect of simvastatin (80 mg) on coronary and abdominal aortic calcium (from the coronary artery calcification treatment with zocor [CATZ] study). Am J Cardiol 99:1714–1717CrossRefPubMed

97.

Maahs DM, Snell-Bergeon JK, Kinney GL et al (2007) ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. J Diab Complicat 21:273–279CrossRef

98.

McIntyre CW (2007) The functional cardiovascular consequences of vascular calcification. Semin Dialysis 20:123–129

99.

Hinchliffe RJ, Kirk B, Bhattacharjee D, Roe S, Jeffcoate W, Game F (2006) The effect of haemodialysis on transcutaneous oxygen tension in patients with diabetes—a pilot study. Nephrol Dial Transplant 21:1981–1983CrossRefPubMed

100.

Game FL, Chipchase SY, Hubbard R, Burden RP, Jeffcoate WJ (2006) Temporal association between the incidence of foot ulceration and the start of dialysis in diabetes mellitus. Nephrol Dial Transplant 21:3207–3210CrossRefPubMed

Titel: Medial arterial calcification in diabetes and its relationship to neuropathy
verfasst von: W. J. Jeffcoate
L. M. Rasmussen
L. C. Hofbauer
F. L. Game
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 12/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-009-1521-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Medial arterial calcification in diabetes and its relationship to neuropathy

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2009

Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors

Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes

Effect of type 2 diabetes on mortality risk associated with end-stage kidney disease

Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C-β activity and TGF-β1 expression

Erratum to: Presence of the APOE ε4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine–Syracuse Study

Heritability and genetic correlations of insulin resistance and component phenotypes in Asian Indian families using a multivariate analysis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin